By Chelsea Naso ( July 27, 2016, 7:04 PM EDT) -- The Federal Trade Commission said Wednesday it will allow Teva to move forward with its planned $40.5 billion acquisition of Allergan's generic business, provided that the Israel-based generics giant sells the rights and assets related to 79 pharmaceutical products....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.